Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponsegromab in Cancer-Related Cachexia
CTR20230543Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ponsegromab in cancer anorexia-cachexia syndrome (CACS), sponsored by Pfizer. Started Feb 2023; status: completed.
02
Drugs
ponsegromab
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on CTR20230543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230543.